Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity,  current microbial and mammalian capabilities, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones. View the video below to hear from Thomas O. Kohl, PhD, our Senior Director of Business Development, on the agility and experience […]

Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity,  current microbial and mammalian capabilities, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones. View the video below to hear from Stijn Cattaert, Director of Business Development, on the agility and experience that make Team Cytovance the ideal

New year, new programs! Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2025 and beyond. View the video below to hear from Rose Rhomberg, Senior Business Development Director,  about our 20+

 This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements. OKLAHOMA CITY, Oklahoma, TORRANCE, California, January 13, 2025 – In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have

Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2024 and beyond. View the video below to hear from Rose Rhomberg, Senior Business Development Director,  about our 20+ years of experience and

Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and high scale-up success rate are helping industry customers meet product milestones in 2024 and beyond. View the video below to hear from Axel Schleyer, CCO, and Brent Van Rite, Sr. Director of Manufacturing, about our

This partnership provides the industry with an integrated solution for customers seeking to outsource cell line development through to cGMP manufacturing of their mammalian-expressed products leveraging the latest available technologies. OKLAHOMA CITY, Oklahoma, UNION CITY, California, July 30, 2024 – To better support the rising demand for development and manufacturing of more complex biologics particularly

This partnership provides the industry with cutting-edge options for mammalian-expressed products. OKLAHOMA CITY, Oklahoma, MONTHEY, Switzerland, May 8, 2024 –  ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based

This best-of-breed partnership will expedite sterile injectables to patients through the optimized transfer of bulk drug substance to finished drug product. Cytovance’s expansion of vetted service providers enables them to meet customers’ needs for a flexible, one-of-a-kind approach and end-to-end solution. OKLAHOMA CITY, Oklahoma, WILMINGTON, NC, December. 11, 2023 – Cytovance Biologics has announced a